Peran Laura, Sierra Saleta, Comalada Mònica, Lara-Villoslada Federico, Bailón Elvira, Nieto Ana, Concha Angel, Olivares Mónica, Zarzuelo Antonio, Xaus Jordi, Gálvez Julio
Department of Pharmacology, University of Granada, Universitario La Cartuja, Spain.
Br J Nutr. 2007 Jan;97(1):96-103. doi: 10.1017/S0007114507257770.
The intestinal anti-inflammatory effects of two probiotics isolated from breast milk, Lactobacillus reuteri and L. fermentum, were evaluated and compared in the trinitrobenzenesulfonic acid (TNBS) model of rat colitis. Colitis was induced in rats by intracolonic administration of 10 mg TNBS dissolved in 50% ethanol (0.25 ml). Either L. reuteri or L. fermentum was daily administered orally (5 x 10(8) colony-forming units suspended in 0.5 ml skimmed milk) to each group of rats (n 10) for 3 weeks, starting 2 weeks before colitis induction. Colonic damage was evaluated histologically and biochemically, and the colonic luminal contents were used for bacterial studies and for SCFA production. Both probiotics showed intestinal anti-inflammatory effects in this model of experimental colitis, as evidenced histologically and by a significant reduction of colonic myeloperoxidase activity (P<0.05). L. fermentum significantly counteracted the colonic glutathione depletion induced by the inflammatory process. In addition, both probiotics lowered colonic TNFalpha levels (P<0.01) and inducible NO synthase expression when compared with non-treated rats; however, the decrease in colonic cyclo-oxygenase-2 expression was only achieved with L.fermentum administration. Finally, the two probiotics induced the growth of Lactobacilli species in comparison with control colitic rats, but the production of SCFA in colonic contents was only increased when L. fermentum was given. In conclusion, L. fermentum can exert beneficial immunomodulatory properties in inflammatory bowel disease, being more effective than L. reuteri, a probiotic with reputed efficacy in promoting beneficial effects on human health.
在大鼠结肠炎的三硝基苯磺酸（TNBS）模型中，对从母乳中分离出的两种益生菌——罗伊氏乳杆菌和发酵乳杆菌的肠道抗炎作用进行了评估和比较。通过向大鼠结肠内注射溶解于50%乙醇（0.25 ml）中的10 mg TNBS诱导结肠炎。在结肠炎诱导前2周开始，每天给每组大鼠（n = 10）口服罗伊氏乳杆菌或发酵乳杆菌（5×10⁸ 菌落形成单位悬浮于0.5 ml脱脂牛奶中），持续3周。通过组织学和生化方法评估结肠损伤，并将结肠腔内容物用于细菌研究和短链脂肪酸（SCFA）生成研究。在该实验性结肠炎模型中，两种益生菌均显示出肠道抗炎作用，组织学证据以及结肠髓过氧化物酶活性显著降低（P<0.05）均可证明。发酵乳杆菌显著对抗了炎症过程诱导的结肠谷胱甘肽耗竭。此外，与未治疗的大鼠相比，两种益生菌均降低了结肠TNFα水平（P<0.01）和诱导型一氧化氮合酶表达；然而，仅在给予发酵乳杆菌时结肠环氧化酶-2表达才降低。最后，与对照结肠炎大鼠相比，两种益生菌均诱导了乳酸杆菌属的生长，但仅在给予发酵乳杆菌时结肠内容物中SCFA的生成才增加。总之，发酵乳杆菌在炎症性肠病中可发挥有益的免疫调节特性，比罗伊氏乳杆菌更有效，罗伊氏乳杆菌是一种在促进对人类健康有益作用方面具有公认功效的益生菌。
